Lipidated immune response modifier compound compositions, formulations, and methods

Abstract

The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl) octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.

1 . A compound of formula: 
       
         
           
           
               
               
           
         
       
       including any pharmaceutically acceptable salt thereof. 
     
     
         2 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of  claim 1 . 
     
     
         3 . A pharmaceutical composition comprising the compound of  claim 1  in a formulation comprising liposomes. 
     
     
         4 . The pharmaceutical composition of  claim 2 , further comprising an antigen. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the compound and antigen are admixed into a single composition. 
     
     
         6 . The pharmaceutical composition of  claim 4 , wherein the compound and antigen are present in separate components of the composition to be administered in combination. 
     
     
         7 . The pharmaceutical composition of any one of  claim 4  wherein the antigen is a cancer vaccine. 
     
     
         8 . The pharmaceutical composition of any one of  claim 4  wherein the antigen is a viral vaccine. 
     
     
         9 . A method of enhancing the effectiveness of a vaccine antigen by administering as a vaccine adjuvant the compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof. 
     
     
         10 . The method of  claim 9 , wherein the compound is incorporated into a liposome formulation. 
     
     
         11 . A method of treating a neoplastic disease, the method comprising administering the compound N-(4-{[4-amino-2-butyl-1H-imidazo [4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof, to a human or animal having the neoplastic disease. 
     
     
         12 . The method of  claim 11 , wherein the compound is in a liposome formulation. 
     
     
         13 . The method of  claim 12 , wherein the formulation is administered directly into a localized tumor mass. 
     
     
         14 . The method of any one of  claim 11 , further including administration of a cancer vaccine antigen.